• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Boule Diagnostics

3.25 SEK

+0.93 %

Less than 1K followers

BOUL

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.93 %
+2.52 %
-17.72 %
-33.81 %
-41.12 %
-59.88 %
-71.39 %
-91.79 %
-64.69 %

Boule Diagnostics operates in the medical technology industry and focuses on the development and manufacture of diagnostic instruments for hematology. The company's products are aimed at healthcare institutions and laboratories. The business is global with a main presence in Europe, North America and Asia. Boule Diagnostics was founded in 1956 and is headquartered in Spånga, Sweden.

Read more
Market cap
126.21M SEK
Turnover
92.17K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

23.10.
2026

Interim report Q3'26

10.2.
2027

Annual report '26

Press release5/29/2026, 6:30 AM

Interim CEO at Boule Diagnostics

Boule Diagnostics
Regulatory press release5/13/2026, 4:00 PM

Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics

Boule Diagnostics
Regulatory press release4/28/2026, 6:00 AM

Boule Diagnostics Interim Report Q1 2026

Boule Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release4/27/2026, 3:00 PM

Boule Diagnostics – Invitation to presentation of the interim report Q1 2026

Boule Diagnostics
Regulatory press release2/11/2026, 7:00 AM

Boule Diagnostics Year-end report 2025

Boule Diagnostics
Press release2/6/2026, 9:30 AM

Boule Diagnostics – Invitation to presentation of the Q4 report 2025

Boule Diagnostics
Press release1/21/2026, 7:30 AM

Boule Diagnostics Renews and Expands a Global Supply Agreement

Boule Diagnostics
Regulatory press release12/30/2025, 7:30 AM

Boule Diagnostics appoints Michael af Winklerfelt as new CFO

Boule Diagnostics
Press release12/22/2025, 10:00 AM

Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy

Boule Diagnostics
Regulatory press release12/5/2025, 7:25 AM

Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter

Boule Diagnostics
Regulatory press release11/21/2025, 3:00 PM

Boule Diagnostics – Nomination Committee for the Annual General Meeting 2026

Boule Diagnostics
Regulatory press release10/24/2025, 6:00 AM

Boule Diagnostics Interim Report Q3 2025

Boule Diagnostics
Press release10/20/2025, 8:45 AM

Boule Diagnostics – Invitation to presentation of the interim report Q3 2025

Boule Diagnostics
Regulatory press release10/13/2025, 6:35 AM

Boule Diagnostics Announces CFO Departure for New Opportunity

Boule Diagnostics
Regulatory press release7/18/2025, 6:00 AM

Boule Diagnostics Interim Report Q2 2025

Boule Diagnostics
Press release7/11/2025, 9:00 AM

Boule Diagnostics – Invitation to presentation of the interim report Q2 2025

Boule Diagnostics
Regulatory press release5/7/2025, 3:45 PM

Bulletin from the Annual General Meeting May 7, 2025 in Boule Diagnostics

Boule Diagnostics
Regulatory press release4/28/2025, 6:00 AM

Boule Diagnostics Interim Report Q1 2025

Boule Diagnostics
Press release4/23/2025, 11:00 AM

Boule Diagnostics – Invitation to presentation of the interim report Q1 2025

Boule Diagnostics
Third party research2/12/2025, 6:22 AM

Boule Diagnostics: A new round of boule(s) with lower costs - ABG

Beat on adj. EBIT but lower OCF Adj. EBIT up 8.9-9.8% for '25e-'26e Trading at 5.6x '25e EV/EBIT Higher volume but lower ASP Boule Diagnostics ended the year with sales of SEK 143.2m (+2% vs. ABGSCe 140.6m), organic growth of -1.8% (ABGSCe -4.3%), a ...

Boule Diagnostics